The global metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.8% during the forecast period. An increasing number of clinical trials have been witnessed over the years owing to the rising prevalence of metabolic disorders and increasing demand for more effective treatment. For instance, in May 2020, POXEL SA, a biopharmaceutical company focused to develop innovative treatments for metabolic disorders, such as non-alcoholic steatohepatitis (NASH) and type 2 diabetes declared new preclinical results for PXL770. It is a direct adenosine monophosphate-activated protein kinase(AMPK) activator, was assessed in a rodent NASH model along with other major agents in development, such as a thyroid receptor ? agonist (MGL-3196), an FXR agonist (obeticholic acid), and a GLP-1 receptor agonist (semaglutide).
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/metabolic-disorder-therapeutics-market
The outcomes feature PXL770 as a potential new NASH therapy that may develop complementary advantages while combined with other agents with different action mechanisms. Further, in September 2020, Kaleido Biosciences, Inc. declared that it has evaluated Microbiome Metabolic Therapy (MMT) candidate KB295 in the first patient suffering from mild-to-moderate ulcerative colitis. Such kinds of clinical studies are offering an opportunity for new launches of innovative therapies for metabolic disorders, which in turn, will further accelerate the market growth.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/metabolic-disorder-therapeutics-market
Global Metabolic Disorder Therapeutics Market-Segmentation
By Therapy
- Drug Therapy
- Gene Therapy
- Cellular Transplantation
- Enzyme Replacement Therapy
- Others
By Disease
- Obesity
- Diabetes
- Lysosomal Storage Disease
- Hypercholesterolemia
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
